Department of Obstetrics and Gynecology, Chia-Yi Chang Gung Memorial Hospital, Chia-Yi, Taiwan.
Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Ta Pei Road, Niao Sung District, Kaohsiung City, 83301, Taiwan, Republic of China.
BMC Womens Health. 2019 Jul 24;19(1):103. doi: 10.1186/s12905-019-0798-y.
Probiotics has been shown to be effective in reducing vaginal colonization of pathogenic organisms. The aim of this study was to investigate the influence of probiotic strains Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on genital high-risk human papilloma virus (HR-HPV) clearance and quality of cervical smear.
This was a randomized, double-blinded, placebo-controlled trial. Women with genital HR-HPV infection were randomized into study and control groups. A probiotic or placebo preparation was administered orally (one capsule daily) until negative HR-HPV testing. A cervical smear and HR-HPV tests were performed at the beginning of the study and every 3 months thereafter until a negative result was obtained.
A total of 121 women with genital HR-HPV infection were enrolled (62 in the study group and 59 in the control group). There was no significant difference in HR-HPV clearance rate between the two groups (58.1% vs. 54.2%). The only factor predicting HR-HPV clearance was a lower initial viral load (HR 3.214; 95% CI: 1.398, 7.392; p = 0.006). Twenty-two women had a mildly abnormal initial cervical smear and nine had an unsatisfactory smear. At 6 months follow-up, both mildly abnormal cervical smear and unsatisfactory smear rates had decreased significantly in the study group compared to the control group (p = 0.017 and 0.027).
The application of probiotic strains Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 did not influence genital HR-HPV clearance, but may have decreased the rates of mildly abnormal and unsatisfactory cervical smears.
Clinicaltrials.gov NCT01599416 , May, 2012. Retrospectively registered.
益生菌已被证明可有效减少致病生物体对阴道的定植。本研究旨在探讨益生菌菌株鼠李糖乳杆菌 GR-1 和罗伊氏乳杆菌 RC-14 对生殖道高危型人乳头瘤病毒（HR-HPV）清除和宫颈涂片质量的影响。
这是一项随机、双盲、安慰剂对照试验。患有生殖道 HR-HPV 感染的女性被随机分为研究组和对照组。口服给予益生菌或安慰剂制剂（每日一粒），直至 HR-HPV 检测阴性。在研究开始时以及此后每 3 个月进行一次宫颈涂片和 HR-HPV 检测，直至获得阴性结果。
共有 121 名生殖道 HR-HPV 感染的女性入组（研究组 62 例，对照组 59 例）。两组的 HR-HPV 清除率无显著差异（58.1%比 54.2%）。唯一预测 HR-HPV 清除的因素是初始病毒载量较低（HR 3.214；95%CI：1.398，7.392；p=0.006）。22 名女性初始宫颈涂片轻度异常，9 名涂片不满意。在 6 个月随访时，与对照组相比，研究组的轻度异常宫颈涂片和不满意涂片率均显著降低（p=0.017 和 0.027）。
应用益生菌菌株鼠李糖乳杆菌 GR-1 和罗伊氏乳杆菌 RC-14 并未影响生殖道 HR-HPV 清除，但可能降低了轻度异常和不满意的宫颈涂片率。
Clinicaltrials.gov NCT01599416，2012 年 5 月，回顾性注册。
